中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
3期
280-282
,共3页
肺疾病,慢性阻塞性%噻托溴铵%沙美特罗%丙酸氟替卡松%BODE指数
肺疾病,慢性阻塞性%噻託溴銨%沙美特囉%丙痠氟替卡鬆%BODE指數
폐질병,만성조새성%새탁추안%사미특라%병산불체잡송%BODE지수
Pulmonary disease,chronic obstructive%Thiazide torsten bromine ammonium%Salmeterol%Propionic acid fluticasone%BODE index
目的 观察沙美特罗替卡松吸入剂联合噻托溴铵干粉吸入剂对中重度稳定期慢性阻塞性肺疾病(COPD)患者BODE指数的影响.方法 47例中重度稳定期COPD患者完全随机分为研究组(25例)和对照组(22例),研究组给予吸入噻托溴铵干粉剂(18 μg,1次/d)与沙美特罗替卡松吸入剂(50/500μg,2次/d),对照组给予吸入噻托溴铵于粉剂(18 μg,1次/d),在治疗前及治疗第2、4和8周末测定BMI、第一秒用力呼气容量占预计值百分比( FEV1％)、呼吸困难量表(MMRC)、6 min步行距离(6MWD)及BODE指数.结果 治疗8周后,研究组BODE指数和MMRC与对照组比较,差异均有统计学意义[(3.0±2.1)比(3.5±2.4),(1.8±0.7)分比(2.0±0.8)分,均P＜0.05].对照组1例出现轻微的口干反应,继续用药3d后自行缓解,研究组1例患者因口腔溃疡经对症处理后缓解继续用药.结论 噻托溴铵联合沙美特罗替卡松吸入剂能明显改善中重度稳定期COPD患者的生活质量且副作用少,值得临床推广.
目的 觀察沙美特囉替卡鬆吸入劑聯閤噻託溴銨榦粉吸入劑對中重度穩定期慢性阻塞性肺疾病(COPD)患者BODE指數的影響.方法 47例中重度穩定期COPD患者完全隨機分為研究組(25例)和對照組(22例),研究組給予吸入噻託溴銨榦粉劑(18 μg,1次/d)與沙美特囉替卡鬆吸入劑(50/500μg,2次/d),對照組給予吸入噻託溴銨于粉劑(18 μg,1次/d),在治療前及治療第2、4和8週末測定BMI、第一秒用力呼氣容量佔預計值百分比( FEV1％)、呼吸睏難量錶(MMRC)、6 min步行距離(6MWD)及BODE指數.結果 治療8週後,研究組BODE指數和MMRC與對照組比較,差異均有統計學意義[(3.0±2.1)比(3.5±2.4),(1.8±0.7)分比(2.0±0.8)分,均P＜0.05].對照組1例齣現輕微的口榦反應,繼續用藥3d後自行緩解,研究組1例患者因口腔潰瘍經對癥處理後緩解繼續用藥.結論 噻託溴銨聯閤沙美特囉替卡鬆吸入劑能明顯改善中重度穩定期COPD患者的生活質量且副作用少,值得臨床推廣.
목적 관찰사미특라체잡송흡입제연합새탁추안간분흡입제대중중도은정기만성조새성폐질병(COPD)환자BODE지수적영향.방법 47례중중도은정기COPD환자완전수궤분위연구조(25례)화대조조(22례),연구조급여흡입새탁추안간분제(18 μg,1차/d)여사미특라체잡송흡입제(50/500μg,2차/d),대조조급여흡입새탁추안우분제(18 μg,1차/d),재치료전급치료제2、4화8주말측정BMI、제일초용력호기용량점예계치백분비( FEV1％)、호흡곤난량표(MMRC)、6 min보행거리(6MWD)급BODE지수.결과 치료8주후,연구조BODE지수화MMRC여대조조비교,차이균유통계학의의[(3.0±2.1)비(3.5±2.4),(1.8±0.7)분비(2.0±0.8)분,균P＜0.05].대조조1례출현경미적구간반응,계속용약3d후자행완해,연구조1례환자인구강궤양경대증처리후완해계속용약.결론 새탁추안연합사미특라체잡송흡입제능명현개선중중도은정기COPD환자적생활질량차부작용소,치득림상추엄.
Objective To observe the effect of salmeterol and propionic acid fluticasone combined with thiazide torsten bromine ammonium dry inhaler on BODE index of moderate to severe stabilization chronic obstructive pulmonary disease(COPD).Methods Forty-seven cases of severe stabilization COPD patients were randomly divided into two groups:treatment group and control group.The treatment group was given inhaled thiazide torsten bromine ammonium dry inhaler and salmeterol and propionic acid fluticasone; the control group was given inhaled thiaside bromide dry powder,respectively.BODE index betore treatment,two weeks,four weeks and eight weeks after treatment was determined.Results After treatment of eight weeks,the BODE index and Modified Medical Research Council Scale ( MMRC ) had significant difference between treatment group and control group [( 3.0 ± 2.1 ) vs (3.5 ± 2.4),( 1.8 ± 0.7 ) scores vs ( 2.0 ± 0.8 ) scores,P ＜ 0.05].Conclusion Salmeterol and propionic acid fluticasone combined with thiazide torsten bromine ammonium dry inhaler can significantly improve the quality of life in patients with moderate stable chronic obstructive pulmonary disease and has low side effects.
